The Consensus of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) recommends GLP-1RA and DPP-4 inhibitors as therapeutics for T2DM treatment. The gene discussed is DPP4; the disease is diabetes mellitus.